Intrinsic Value of S&P & Nasdaq Contact Us

NuCana plc NCNA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • GB • USD

SharesGrow Score
50/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

NuCana plc (NCNA) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 7 Buy, 1 Hold.

Analysts estimate Earnings Per Share (EPS) of $-80.00 and revenue of $0.00B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-3.27 vs est $-80.00 (beat +95.9%). 2025: actual $-7.75 vs est $-8.00 (beat +3.1%). Analyst accuracy: 0%.

NCNA Analyst Ratings

Buy
8
Ratings
7 Buy
1 Hold
Based on 8 analysts giving stock ratings to NuCana plc in the past 3 months
Rating breakdown
Buy
7 88%
Hold
1 13%
88%
Buy
7 analysts
13%
Hold
1 analysts
0%
Sell
0 analysts

EPS Estimates — NCNA

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$3.27 vs Est –$80.00 ▲ 2,346.5% off
2025 Actual –$7.75 vs Est –$8.00 ▲ 3.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — NCNA

Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message